AOD 9604

ADVANCED OBESITY DRUG (MODIFIED PEPTIDE FRAGMENT OF HGH)

• Molecular Formula:C78H123N23O23S2
• Molecular Weight: 1815.1
• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

DESCRIPTION

AOD 9604 is a modified form of amino acids 176-191 of the GH proteins. Investigators at Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176- 191, is less than 10% of the total size of the GH Molecule and appears to have no effect on growth or insulin resistance.

This hypothesis was proven in animals to a tremendous degree with specimen losing a significant amount of fat mass. However, in phase three clinical trials the peptide didn’t mean its confidence interval. Instead, it is now being studied for its effect on bone and cartilage. AOD 9604 possesses many other regenerative properties associated with growth hormone. Currently, trials are underway to show the application of AOD 9604 in osteoarthritis, Hypercholesterolemia, bone and cartilage repair & pain. AOD 9604 has an excellent safety profile, recently obtaining Human GRAS status in the USA.

PROTOCOL

• Content & Potency: 1200mcg/ml subcutaneous injectable provided in a 5ml vial
• Suggested dosage: Suggested dosage:Inject 0.25ml subcutaneously once daily for 20 days.

CLINICAL RESEARCH

Safety and Tolerability of the Hexadecapeptide AOD 9604 in Humans

Heike Stier, Evert Vos, David Kenley

Background:The human growth hormone (hGH) has fat loss properties making ita potential candidate to treat obesity. AOD 9604 is a peptide fragment of theC-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity ofhGH, without its negative effects. In this paper the safety data of AOD 9604obtained in clinical trials are summarized.

Methods:Six randomized, double-blind, placebo-controlled trials were performedwith AOD 9604. Special focus was given to undesired effects associated with hGH

Treatment:increases in IGF-1 levels, insulin resistance, and impaired glucosetolerance. Blood samples were analyzed for presence of antiAOD 9604 antibodiesto exclude immunogenicity.

Results:AOD 9604 had no effect on serum IGF-1 levels, which confirms thehypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerancetest demonstrated that, in contrast with hGH, AOD 9604 has no negative effect oncarbohydrate metabolism. There were no anti-AOD 9604 antibodies detected inany of the patients selected for antibody assay. In none of the studies did awithdrawal or serious adverse event occur related to intake of AOD 9604.

Conclusion:AOD 9604 displayed a very good safety and tolerability profileindistinguishable from placebo. AOD 9604 did not result in any of the adverseeffects associated with full-length hGH treatment.

AOD 9604 Research

Here are some examples of research studies that have been conducted on the peptide AOD 9604:

1. A study on the effects of AOD 9604 on lipolysis and body weight in obese individuals: https://www.ncbi.nlm.nih.gov/pubmed/19912190
2. A research article describing the use of AOD 9604 as a potential treatment for osteoarthritis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175631/
3. A study on the safety and efficacy of AOD 9604 in healthy human volunteers: https://www.ncbi.nlm.nih.gov/pubmed/18616514
4. A review article on the potential therapeutic applications of AOD 9604: https://www.ncbi.nlm.nih.gov/pubmed/21814562
5. A study on the effects of AOD 9604 on bone healing and regeneration in a rat model of bone defects: https://www.ncbi.nlm.nih.gov/pubmed/27018006

Please note that this is not an exhaustive list and there may be other studies that have been conducted on AOD 9604.